AMAG Pharmaceuticals, Inc. provided earnings guidance for the fourth quarter and full year of 2012 and for the year 2013. For the fourth quarter of 2012, the company expects total revenues of between $21.1 million and $21.5 million, including between $14.4 million and $14.8 million of net U.S. Feraheme product revenues. The approximate 14% growth in U.S. net product revenues, compared to the fourth quarter of 2011, was driven by increased volume and an improving net effective price per gram for Feraheme.

For the year 2012, the company expects to report 2012 full year financial results in line with previous guidance, which was positively updated over the course of the year.

For the year 2013, the company expects to report total revenues of between $73 million and $77 million, including: Feraheme U.S. net product revenues of between $63 million and $67 million, driven by a combination of price and double-digit volume growth; Royalties and product sales related to ex-U.S. sales of Feraheme/Rienso and recognition of milestones of approximately $10 million.